Advertise on podcast: European Pharmaceutical Review podcast

In this podcast, recorded ahead of International Women’s Day, Biogen’s Dr Kylie Bromley reflects on her career in the pharmaceutical sector and shares valuable insight into how the industry can work together to build greater gender equality and diversity.

In this podcast, Manu Kittanakere, Associate Director of Packaging Engineering at Gilead discusses the future of pharmaceutical packaging, including the growing importance of AI, automation and sustainability in packaging engineering.

In this episode, Dr Salim Benkhalifa, Medical Affairs Lead, Celltrion Healthcare France reflects on biosimilars development, highlighting the three core challenges facing the sector and how they might be overcome.

In this podcast, Paul Nioi, Vice President of Discovery and Translational Research at Alnylam Pharmaceuticals discusses the clinical development and manufacturing of RNA interference (RNAi) therapeutics. RNA interference (RNAi) medicines that can ‘silence’ or turn off the production of specific genes that cause or contribute to disease, are one of the exciting emerging modalities in drug development today. In this episode, EPR Editor Caroline Peachey catches up with Dr Paul Nioi, Vice President of Discovery and Translational Research at Alnylam Pharmaceuticals to explore clinical development and manufacturing of RNAi medicines for large patient populations.

In this podcast, Allison Scott, Lynn Johnson and Miriam Guest of the Modern Microbial Methods Collaboration discuss how cross-industry collaboration through working groups can support adoption of modern microbial methods.

Continuous manufacturing (CM) is recognised industry wide as a more efficient and flexible manufacturing approach than batch manufacturing. Yet, despite encouragement from regulators and being standard in many industries, the pharmaceutical sector has been quite slow to adopt continuous manufacturing techniques. In this episode, Patricia Hurter, CEO of Lyndra Therapeutics, discusses how the pharmaceutical sector can embrace continuous manufacturing. She also shares her tips for women looking to progress their careers in pharma.

Antimicrobial resistance (AMR) is a growing concern worldwide and is recognised as one of the leading health challenges by the World Health Organization (WHO). With drug resistant infections contributing to nearly 5 million deaths every year and costing the European Union (EU) an estimated €1.5 billion per year in healthcare costs and productivity losses, AMR is both a scientific and economic issue. In this episode, Dr Boumediene Soufi, Head of Antimicrobial Resistance at Sandoz, discusses the challenge of AMR and some of the actions being taken by Sandoz and the wider pharmaceutical industry to address this issue.

In this episode, Félix Montero Julian, the Scientific Director for the Healthcare Business of bioMérieux and Thomas Jones, Cell & Gene Therapy Business Senior Director at bioMérieux discuss the evolving needs of quality control (QC) for cell and gene therapy (CGT) and how these developments are supporting efforts to scale up manufacturing.

How is the implementation of artificial intelligence, machine learning and virtual reality shaping the microbiology lab of the future? What do these innovations mean for personnel? Find out in this episode with AstraZeneca... As Pharma 4.0 becomes a reality, a diverse array of technologies have emerged to enhance industrial processes, from the internet of things to artificial intelligence, machine learning and virtual reality. In this episode AstraZeneca's Sophie Bailes, Associate Director for Digital Transformation and Miriam Guest, Principal Microbiologist, Pharmaceutical Technology & Development, share how these innovations are changing the the microbiology lab and aseptic manufacturing practices for the future.

What unmet need remains in breast cancer and how is drug development helping tackle these challenges? Tune in to this episode with Daiichi Sankyo to find out more. Despite therapeutic advancement over the last few years, unmet need in breast cancer still remains. In this podcast, Professor Dr Markus Kosch, Head, Oncology Business Division Europe at Daiichi Sankyo, discusses the challenges associated with breast cancer treatment and some of the recent therapeutic developments that may help overcome them - highlighting the potential role of antibody-drug conjugates (ADCs).

Discover the common compliance concerns encountered when using spectroscopy instruments for QC, as well as how to rectify them in this episode with Agilent Technologies. While we all know regulatory compliance is crucial, it can be challenging to meet the expectations within the highly regulated pharmaceutical industry. With spectroscopy instruments being a crucial pharmaceutical analysis tool, and their applications across the pharma industry growing, in this episode Agilent Technologies' Julia Griffen, Product Manager Raman Products and Garry Wright, European Laboratory Compliance Specialist, highlight some of the common compliance issues companies are facing when leveraging spectroscopy for QC and what to do to overcome them.

Tune in to discover how and why digital twins are being developed and used in pharmaceutical development and manufacturing. As the industry works to establish interconnectivity leveraging automation, machine learning and real-time data in the transition to Pharma 4.0, digital twins have emerged as a solution to increase productivity and efficiency in drug development and manufacturing, while also enhancing quality. In our latest episode, Loredana Vagaggini, Senior Manager Principal Product Owner, Vx Tech R&D at GSK discusses the use of digital twins in pharmaceutical development and manufacturing.